Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO4995819
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01901159
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 61
- Registration Number
- NCT01901172
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01898585
- Locations
- πΏπ¦
Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, South Africa
πΏπ¦Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa
πΏπ¦Mary Potter Oncology Centre, Groenkloof, South Africa
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01898598
- Locations
- πΊπΈ
Loma Linda University Medical Center, Loma Linda, California, United States
πΊπΈMayo Clinic, Scottsdale, Arizona, United States
πΊπΈUniversity of Minnesota, Minneapolis, Minnesota, United States
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01897038
A Study of RO6799477 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO6799477
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT01893437
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)
Phase 3
Withdrawn
- Conditions
- Diabetes Mellitus Type 2, Kidney Disease, Chronic
- Interventions
- Drug: AleglitazarDrug: Placebo
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01893242
An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 279
- Registration Number
- NCT01893268
- Locations
- π«π·
Clinique Du Docteur Calabet; Cromg, Agen, France
π«π·Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire, Aix En Provence, France
π«π·HOPITAL JEAN MINJOZ; Oncologie, Besancon, France
A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)
Withdrawn
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01893255
A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis
- Conditions
- Anemia
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01892202
Β© Copyright 2025. All Rights Reserved by MedPath